Lower injection‐site reactions and long‐term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post‐hoc analysis of a double‐blind, randomized, phase III comparative study and its open‐label extension in patients with rheumatoid arthritis

AIM: YLB113 biosimilar was evaluated in an open‐label extension single‐arm study to assess long‐term safety, efficacy, and immunogenicity in patients with rheumatoid arthritis (RA). We also report post‐hoc results on the incidence of injection‐site reactions (ISRs) and injection‐site erythema (ISE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Hisashi, Tanaka, Yoshiya, Hibino, Toshihiko, Unmesh, Gopalakrishnan, Shah, Chirag, Bakhle, Dhananjay, Stefanidis, Dimitris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092464/
https://www.ncbi.nlm.nih.gov/pubmed/36253032
http://dx.doi.org/10.1111/1756-185X.14462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092464/
https://www.ncbi.nlm.nih.gov/pubmed/36253032
http://dx.doi.org/10.1111/1756-185X.14462

Ejemplares similares